HARROW, INC.HROWEarnings & Financial Report
Harrow Health, Inc., formerly known as Imprimis Pharmaceuticals, is a publicly traded pharmaceutical company based in Nashville, Tennessee.
Revenue
$63.7M
Gross Profit
$47.5M
Operating Profit
$11.4M
Net Profit
$5.0M
Gross Margin
74.5%
Operating Margin
17.9%
Net Margin
7.8%
YoY Growth
30.2%
EPS
$0.13
HARROW, INC. Q2 FY2025 Financial Summary
HARROW, INC. reported revenue of $63.7M (up 30.2% YoY) for Q2 FY2025, with a net profit of $5.0M (up 177.2% YoY) (7.8% margin). Cost of goods sold was $16.2M, operating expenses totaled $36.1M.
Key Financial Metrics
| Total Revenue | $63.7M |
|---|---|
| Net Profit | $5.0M |
| Gross Margin | 74.5% |
| Operating Margin | 17.9% |
| Report Period | Q2 FY2025 |
Revenue Breakdown
HARROW, INC. Q2 FY2025 revenue of $63.7M breaks down across 4 segments, led by Compounding at $21.5M (33.7% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Compounding | $21.5M | 33.7% |
| VEVYE | $18.6M | 29.2% |
| IHEEZO | $18.3M | 28.8% |
| Other Products | $5.2M | 8.2% |
HARROW, INC. Revenue by Segment — Quarterly Trend
HARROW, INC. revenue by segment across the last 4 reported quarters, showing how each business line (such as Compounding and VEVYE) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Compounding | — | $20.1M | $21.5M | — |
| VEVYE | — | $22.6M | $18.6M | — |
| IHEEZO | — | $21.9M | $18.3M | — |
| Other Products | — | $6.9M | $5.2M | — |
HARROW, INC. Annual Revenue by Year
HARROW, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $272.3M).
| Year | Annual Revenue |
|---|---|
| 2025 | $272.3M |
| 2024 | $199.6M |
| 2023 | $130.2M |
| 2022 | $88.6M |
HARROW, INC. Quarterly Revenue & Net Profit History
HARROW, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $89.1M | +33.3% | $6.6M | 7.4% |
| Q3 FY2025 | $71.6M | +45.4% | $1.0M | 1.4% |
| Q2 FY2025 | $63.7M | +30.2% | $5.0M | 7.8% |
| Q1 FY2025 | $47.8M | +38.3% | $-17.8M | -37.2% |
| Q4 FY2024 | $66.8M | +83.8% | $6.8M | 10.1% |
| Q3 FY2024 | $49.3M | +43.8% | $-4.2M | -8.6% |
| Q2 FY2024 | $48.9M | +46.2% | $-6.5M | -13.2% |
| Q1 FY2024 | $34.6M | +32.5% | $-13.6M | -39.2% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $34.6M | $48.9M | $49.3M | $66.8M | $47.8M | $63.7M | $71.6M | $89.1M |
| YoY Growth | 32.5% | 46.2% | 43.8% | 83.8% | 38.3% | 30.2% | 45.4% | 33.3% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $295.5M | $306.6M | $351.5M | $389.0M | $364.2M | $345.0M | $363.1M | $399.5M |
| Liabilities | $235.3M | $248.5M | $293.9M | $319.7M | $308.1M | $295.7M | $316.4M | $347.4M |
| Equity | $60.6M | $58.5M | $58.0M | $69.7M | $56.5M | $49.7M | $47.0M | $52.4M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-4.6M | $-2.7M | $3.0M | $-17.8M | $19.7M | $-803000 | $16.6M | $8.4M |